International Journal of Research in Pharmacology & Pharmacotherapeutics

ISSN Print: 2278-2648 IJRPP |Vol.10 | Issue 3 | Jul - Sep - 2021
ISSN Online: 2278-2656 Journal Home Page: www.ijrpp.com

Review article Open Access

Review on ivermectin

A.Hussain[1], SP.Senthil[2], M.Sakthivel[3], R.Senthamarai[4]

Department of Pharmaceutics, Periyar College of Pharmaceutical Science, the Tamilnadu MGR Medical University, India

Corresponding author: A.Hussain
Email: hussainrock17@gmail.com

ABSTRACT

Ivermectin is an antiparasitic drug that is a synthetic version of avermectin. It is used in veterinary medicine and to treat onchocerciasis in humans. It binds to glutamate gated chloride channels and has now been targeted to treat the microfilaria stage of various parasites. The US Food and Drug Administration have approved ivermectin lotion for the treatment of pediculosis capitis. Oral ivermectin is used to treat phthiriasis palpebraum and is effective against a wide variety of nematodes and insects, as well as acarine of animals and humans.

Keywords: Ivermectin, onchocerciasis, microfilaria, capitis scabies, filariasis.

INTRODUCTION

Ivermectin is a potent macro-cyclic lactone and affects many nematodes and arthropods in causing chloride ions to diffuse through cell membranes. It is currently the drug of choice for human onchocerciasis, it has potent microfilaricidal activity against the other major filarial parasites of humans (Wuchereriabancrofti, Brugiamalayi, Loa, and Mansonellaozzardi), but not against the other major filarial parasites of humans (Wuchereriabancrofti, Brugiamalayi, Loa loa, and MansonellaozzardM. perstans, however, is not one of them. It is currently being investigated whether it also destroys the adult stage of these parasites. Ivermectin also has excellent efficacy against the intestinal nematodes Ascarislumbricoides and Trichurismigrans, for which there are no successful alternative treatments; and it is as effective as currently available medications against the intestinal nematodes Ascarislumbricoides and Trichurismigrans. Trichiura and Enterobiusvermicularis; it is only partially effective against human hookworms. Ivermectin has the potential to become the drug of choice for ectoparasitic infestations (mites, lice) in humans, according to preliminary research.[1]

Ivermectin (MK-0933, 22, 23-dihydroderivative of amvermectin B1) is a synthetic derivative of the avermectins, which are a broad-spectrum antiparasitic class of macro cyclic lactones. Avermectin B was discovered by fermenting the actinomycete Streptomyces avermitilis, a soil microorganism. Ivermectin has a structure that is similar to macrolide antibiotics, but it does not have antibacterial properties.

Although ivermectin has a wide range of applications in veterinary medicine, it is almost exclusively used to treat onchocerciasis in humans. Its role as the drug of choice in onchocerciasis is based entirely on its activity against the skin-dwelling first stage larvae (microfilariae) of *Onchocerca volvulus*, despite its activity against various life-cycle stages of many nematodes. Of course, the drug's possible utility in other human parasitic infections has piqued people's interest. Efficacy against various human parasites has been studied in both laboratory and clinical trials over the last decade, and it's time to see where the findings are heading. We reviewed existing pharmacokinetics and pharmacodynamics principles to help address this query. The biochemical mechanism of action, as well as clinical data that suggests additional applications in human medicine.

STRUCTURE



MECHANISM OF ACTION

GLUTAMATE GATED CHLORIDE CHANNEL

Ivermectin binds to glutamate-gated chloride channels found in invertebrate nerve and muscle cells with a high affinity, increasing the permeability of the cell membrane to chloride ions as the nerve or muscle cell hyperpolarizes. Hyperpolarization causes paralysis and parasite death, either directly or indirectly by starving the worms however; at least one study suggests that Ivermectin has a depolarizing rather than hyperpolarizing effect on the glutamate-gated chloride channel. In either case, the manipulation of chloride levels results in the deactivation of the tube

SELECTIVITY

Since certain mammals lack glutamate-gated chloride channels and avermectins have a low affinity for mammalian ligand-gated chloride channels, this class of compounds has a selective activity. Furthermore, in humans, ivermectin does not readily cross the blood-brain barrier, instead targeting its antiparasitic function to the general circulation.

TARGETED ORGANISM

Ivermectin is primarily used to treat the microfilaria stage of various parasites. Many, but not all, nematodes are susceptible to ivermectin at different stages of their life cycle. It's up and running fighting Onchocerca volvulus tissue microfilariae it only works against the intestinal stages of Strongyloidesstercoralis. Although the macrofilaricidal effect of Ivermectin is debatable, there is evidence that it has a macrofilaricidal effect in Onchocerca volvulus. Due to a direct, anthelminthic effect, a 3-monthly regimen appeared to cause an increase in adult female worm death. Ivermectin'smacrofilaricdal effect, or by increasing the prevalence and severity of a potentially fatal pleomorphic ovarian neoplasm (PN) In nematode studies, especially in Trichinellaspiralis, there is evidence that ivermectin works by blocking signal transmission from interneurons to excitatory motoneurons, with GABA as the neurotransmitter being blocked[2, 3, 4, 5]

PHARMACOLOGICAL ACTION

It is quickly ingested when taken orally on an empty stomach, metabolised in the liver, and excreted in the faeces (98%) and urine (98%) respectively (1 percent). Human milk has been shown to have a very low concentration of this compound. The concentration of ivermectin in the blood peaks at 30 - 46 ng/mL about 4 hours after the doses and then gradually decreases.[6, 7]The metabolite's peak plasma concentration lasts longer than the parent drug's, implying enterohepatic recycling. Fat, skin, subcutaneous fascia, and nodules[8] all contained ivermectinIvermectin has a half-life of 36 hours and hits peak plasma levels 5 hours after oral administration[9].After a single 12-mg oral dose, the drug concentration in squames, sebum, and sweat on the forehead and the antithenar peaked at 8 hours and then declined after 24 hours.[10]

SAFETY AND ADVERSE REACTIONS

Anorexia, asthenia, headache, arthralgia, myalgia, fever, and eosinophilia have been identified in 24% of filarial disease patients, with signs and symptoms such as anorexia, asthenia, headache, arthralgia, myalgia, fever, and eosinophilia. Mazzotti reactions and sudden death from the release of microfilaria degradation products have been observed in filarial disease patients[11].Patients with scabies experienced macular and papular rashes and pruritus (33 percent) between 2 and 4 days after taking oral ivermectin. (The release of toxic compounds from dying or dead mites causes this adverse reaction.) In a few patients, hematomas and an increase in prothrombin duration have been found. Nausea and a drop in blood pressure are common side

effects. Flat T waves and prolonged PR times on the ECG have also been recorded[12]

DRUG INTERACTIONS

Infested patients received a single dose of anthelmintic (200µg /kg) and antibacterial (100 mg/kg, daily for 6 weeks) to keep microfiladermia levels low for longer than ivermectin alone. Ivermectin-induced suppression was improved by doxycycline Microfiladermia sterilises adult female worms for a period of time Depletion of symbiotic endobacteria of filariae, Wolbachia spp. (essential for filariae survival and reproduction)[13] for a few months
In onchocerciasis patients, the antiparasitic efficacy of a single ivermectin dose (150 µg /kg, on day 1) supplemented by amorcazine (3 mg/kg twice daily, on days 8, 9 and 10) was comparable to that of ivermectin alone. 19 Similarly, a mixture of ivermectin (200 µg /kg) and levamisole (2.5 mg/kg) was neither macrofilaricidal nor more effective against microfilariae While levamisole increased ivermectin plasma bioavailability in these patients,[14] it had a lower effect on microfilariae and adult worms than ivermectin alone. In humans, the efficacy of available drugs for treating Trichuristrichiura infection is limited. Treatment with albendazole (400 mg) and ivermectin (200 µg /kg) in a single dose tends to be more effective than albendazole alone or diethylcarbamazine (6 mg/kg)[15] in preventing trichuriasis. As a result, ivermectin interactions with other drugs taken at the same time are possible. As antiparasitic drug resistance spreads,[16] this problem became increasingly significant. When using insecticides, a man who had been on long-term oral anticoagulant therapy with acenocoumarol demonstrated persistent, excessive hypocoagulability (ivermectin and metidation)Trees cannot be treated without defence. These kinds of encounters are possible, and they may lead to hemorrhagic complications.
Alcohol has no impact on ivermectin kinetic behaviour; however, because of ivermectin's interaction with GABA receptors and alcohol's effect on the central nervous system, co-ingestion of alcoholic beverages is not recommended.Ivermectin[17] (150 µg /kg) was given to 16 people with either water or orange juice (750 ml). Since fruit juices and constituents are potent inhibitors of some drug transporters, orange juice decreased AUC (15.7 ng.d.ml -1) and Cmax (20.7 ng.d.ml -1)[18]

CONTRAINDICATIONS

PREGNANCY AND LACTATION

In humans, the efficacy of ivermectin during pregnancy and lactation has yet to be determined. It's a drug in the pregnancy group C[19]

CHILDREN

It is not recommended for children under 15 kg and less than 5 years of age because the protection and efficacy for use in children under 15 kg has not been identified .[20]

OTHER CONDITIONS

Ivermectin can be avoided by people who have had previous shunt surgery or have a history of seizure disorders.[21]

THERAPEUTIC APPLICATION

1. SCABIES

For scabies, ivermectin is the only oral drug that is prescribed[22].To treat newly hatched scabietic nymphs; two doses of oral ivermectin are administered seven days apart. It's often mixed with topical drugs like permethrin in serious or resistant situations.[23]Two doses of topical ivermectin were found to be just as effective as two permethrin applications.[24]

2. PEDICULOSIS

The US Food and Drug Administration (FDA) have approved ivermectin lotion (0.5 percent) for the treatment of pediculosiscapitis. It's best to use a single application on dry hair without nit combing. Ivermectin doses are taken orally[25, 26]
Oral ivermectin has been shown to be involved in the treatment of phthiriasispalpebrarum. Adult lice are killed in two days, but nits fade away over time. It is given as 250–400 g/kg tablets 7 days apart in phthiris pubis, depending on the severity. Topical ivermectin is also safe, and it is recommended that you reapply it every 7–10 days until no live lice are found for at least 1 week.
In cases of demodicosis, both oral and topical ivermectin are safe. 3 Oral ivermectin is the treatment of choice in HIV-related cases[27]

3. ROSACEA

The US FDA has now approved ivermectin 1 percent cream for inflammatory rosacea. Ivermectin not only kills Demodexfolliculorum, but it also helps to reduce the inflammation that comes with it[28]
Cheyletielladermatitis
In households with many cats, ivermectin is successful at controlling Cheyletiella species infestations. The dermatitis that the mites cause in humans goes away on its own within three weeks of the mites being removed. In humans, oral ivermectin can be used to prevent disease recurrence[29]

4. MYIASIS

The purpose of treatment for furuncularmyiasis is to completely remove the larvae from the skin. Topical ivermectin is used first, followed by manual removal. Oral treatment is not recommended because the dead larva in the skin may cause an inflammatory reaction. When it comes to migratory myiasis, the parasite will be mobilised to the body surface if you take ivermectin orally. Wound myiasis necessitates manual larva removal and necrotic tissue debridement. The use of topical ivermectin for short contact will reduce discomfort in 15 minutes and kill the majority of the larvae. A single oral dose of ivermectin will aid in the removal of Hypodermalineatum maggots by inducing maggot migration[29]

5. FILARIASIS

Antifilarial drugs should be given to people who have filariasis and have a positive immunochromatographic test or who have microfilaremia. Microfilaria is killed quickly by ivermectin, but the adult worm is not affected. For successful treatment, the World Health Organization suggests combining albendazole and ivermectin. It was discovered that diethylcarbamazine can be used together. To be more effective than individual drugs[30]

6. ONCHOCERCIASIS

Ivermectin is a drug that is used to treat endemic onchocerciasis. However, only the larva is killed, not the adult. As long as there is proof of skin or eye infection, it is issued every six months. Further doses should be administered at 6–12 monthly intervals if there is a recurrence, pruritus, rash, or eosinophilia[31]

7. CUTANEOUS LARVA MIGRANS

A single oral dose of ivermectin ensures a cure rate of 77 percent to 100 percent. After one or two supplementary doses, the cure rate rises to 97 percent–100 percent. The formation of the tract comes to an end after two days. In the case of hookworm folliculitis, a single dose of ivermectin is less effective[32]

8. STRONGYLOIDOSIS

Oral ivermectin is the first-line therapy for both acute and chronic strongyloidosis. In cutaneous larva currens, two days of oral ivermectin therapy is found to be more successful. Immunosuppressive treatment should be stopped or decreased in cases of hyperinfection syndrome, and regular oral ivermectin should be started before stool and/or sputum tests are negative for 2 weeks. 6[32]

9. LOASIS

Prior to the administration of DEC, ivermectin is used to minimisemicrofilaremia. In patients with Loa loamicrofilaremia>30,000/mL, however, ivermectin administration may cause encephalopathy. When co-infection with Onchocerca volvulus is suspected or confirmed, this is the recommended treatment. It not only treats onchocerciasis, but it also helps to relieve pruritus and calabar swelling Microfilaremia levels were reduced to less than 2000 mf/mL.[33]

MARKETED PRODUCTS

Tabel 1: for humans

Products	Brand name	Mfg by	Uses
Ivermectin lotion	Sklice	Arbor pharmaceuticals	Head lice, Rosacea
	Iversafe	Rockmerd pharma	
	Iverzine	Unipharma	
Ivermectin cream	IVERA1	Ajanta pharma	Head lice, Rosacea
	Iverasafe	Rockmerd pharma	
	Liv mac	Livealth biopharma	
	Soolantra	Galderma laboratories	
	Scabouer	Brinton pharmaceuticals	
Ivermectin tablet	Stromectol	Merck sharp and Dohme corp	River blindness, Parasitic infection
	Iverwell 6	Wellona pharma	

Tabel 2: For animals

Products	Brand name	Mfg by	Uses
NEOMAC tablets	NEOMAC	Intas pharmaceuticals	Treatment of endoparasites and ectoparasites
CORECTIN tablets	CORECTIN	Corise canine care	Prevention and treatment of exteranal and interanal parasites
IVOMEC injection	IVOMEC	Baehringer ingelhem	Treatment and control of gastrointestinal round worms

CONCLUSION

Ivermectin is used to treat a variety of dermatological disorders. Systematic ivermectin administration has many benefits over conventional treatment for scabies, pediculosis, demodicidosis, larva migrans, myiasis, felariasis, and other parasitic infections. More research is needed to determine the best therapeutic uses for dermatology. It was used to characterize infection in humans and animals (insects and worms)

REFERENCES

1. del Giudice P, Marty P. Ivermectin: a new therapeutic weapon in dermatology? Arch Dermatol. 1999 Jun 1; 135(6):705-6. doi: 10.1001/archderm.135.6.705, PMID 10376699.
2. Turner MJ, Schaeffer JM. Mode of action of ivermectin. InIvermectin and Abamectin 1989 (pp. 73-88). New York: Springer.
3. Dent JA, Davis MW, Avery L. Avr 15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans. EMBO J. 1997 Oct 1; 16(19):5867-79. doi: 10.1093/emboj/16.19.5867, PMID 9312045.
4. Burkhart CN, Burkhart CG. Ivermectin: a few caveats are warranted before initiating therapy for scabies. Arch Dermatol. 1999 Dec 1; 135(12):1549-50. doi: 10.1001/archderm.135.12.1549, PMID 10606071.
5. Campbell WC. Ivermectin, an antiparasitic agent. Med Res Rev. 1993 Jan; 13(1):61-79. doi: 10.1002/med.2610130103, PMID 8416263.
6. Edwards G, Dingsdale A, Helsby N, Orme ML, Breckenridge AM. The relative systemic availability of ivermectin after administration as capsule, tablet, and oral solution. Eur J Clin Pharmacol. 1988 Nov; 35(6):681-4. doi: 10.1007/BF00637608, PMID 3234475.
7. Fink DW, Porras AG. Pharmacokinetics of ivermectin in animals and humans. InIvermectin and Abamectin 1989 (pp. 113-30). New York: Springer.
8. González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J. 2008 Mar;10(1):42-6. doi: 10.1208/s12248-007-9000-9, PMID 18446504.
9. Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996 Jul;50(5):407-10. doi: 10.1007/s002280050131, PMID 8839664.
10. Haas N, Lindemann U, Frank K, Sterry W, Lademann J, Katzung W. Rapid and preferential sebum secretion of ivermectin: a new factor that may determine drug responsiveness in patients with scabies. Arch Dermatol. 2002 Dec 1;138(12):1618-9. doi: 10.1001/archderm.138.12.1618, PMID 12472363.
11. Chhaiya SB, Mehta DS, Kataria BC. Ivermectin: pharmacology and therapeutic applications. Int J Basic Clin Pharmacol. 2012 Nov;1(3):132-9. doi: 10.5455/2319-2003.ijbcp002712.
12. Paasch U, Haustein UF. Management of endemic outbreaks of scabies with allethrin, permethrin, and ivermectin. Int J Dermatol. 2000 Jun;39(6):463-70. doi: 10.1046/j.1365-4362.2000.00990.x, PMID 10944095.
13. Hoerauf A, Mand S, Adjei O, Fleischer B, Büttner DW. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet. 2001 May 5;357(9266):1415-6. doi: 10.1016/S0140-6736(00)04581-5, PMID 11356444.
14. Awadzi K, Edwards G, Opoku NO, Ardrey AE, Favager S, Addy ET, Attah SK, Yamuah LK, Quartey BT. The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus. Ann Trop Med Parasitol. 2004 Sep 1;98(6):595-614. doi: 10.1179/000349804225021370, PMID 15324466.
15. Ismail MM, Jayakody RL. Efficacy of albendazole and its combinations with ivermectin or diethylcarbamazine (DEC) in the treatment of Trichuris trichiura infections in Sri Lanka. Ann Trop Med Parasitol. 1999 Jul 1;93(5):501-4. doi: 10.1080/00034989958230, PMID 10690245.
16. González Canga A, Sahagún Prieto AM, Diez Liébana MJ, Fernández Martínez N, Sierra Vega M, García Vieitez JJ. The pharmacokinetics and interactions of ivermectin in humans—a mini-review. AAPS J. 2008 Mar;10(1):42-6. doi: 10.1208/s12248-007-9000-9, PMID 18446504.
17. Shu EN, Onwujekwe EO, Okonkwo PO. Do alcoholic beverages enhance availability of ivermectin? Eur J Clin Pharmacol. 2000 Aug 1;56(5):437-8. doi: 10.1007/s002280000120, PMID 11009055.
18. Vanapalli SR, Chen Y, Ellingrod VL, Kitzman D, Lee Y, Hohl RJ, Fleckenstein L. Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. Clin Pharmacol Ther. 2003 Feb;73(2):P94--. doi: 10.1016/S0009-9236(03)90702-8.
19. Gowtham S, Karthikeyan K. Wonder drug for worms: a review of three decades of ivermectin use in dermatology. Indian J Dermatol Venereol Leprol. 2019 Nov 1;85(6):674-8. doi: 10.4103/ijdvl.IJDVL_840_18, PMID 31552839.
20. Wilkins AL, Steer AC, Cranswick N, Gwee A. Question 1: is it safe to use ivermectin in children less than five years of age and weighing less than 15 kg? Arch Dis Child. 2018 May 1;103(5):514-9. doi: 10.1136/archdischild-2017-314505, PMID 29463522.
21. Dang K, Tribble AC. Strategies in infectious disease prevention and management among US-bound refugee children. Curr Probl Pediatr Adolesc Health Care. 2014 Aug 1;44(7):196-207. doi: 10.1016/j.cppeds.2014.03.004, PMID 25042432.
22. Chhaiya SB, Patel VJ, Dave JN, Mehta DS, Shah HA. Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies. Indian J Dermatol Venereol Leprol. 2012 Sep 1;78(5):605-10. doi: 10.4103/0378-6323.100571, PMID 22960817.
23. Sangaré AK, Doumbo OK, Raoult D. Management and treatment of human lice. BioMed Res Int. 2016 Jul 27;2016:8962685. doi: 10.1155/2016/8962685, PMID 27529073.
24. Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, Burgess I. Oral ivermectin versus Malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010 Mar 11;362(10):896-905. doi: 10.1056/NEJMoa0905471, PMID 20220184.

25. Salavastru CM, Chosidow O, Janier M, Tiplica GS. European guideline for the management of pediculosis pubis. J Eur Acad Dermatol Venereol. 2017 Sep;31(9):1425-8. doi: 10.1111/jdv.14420, PMID 28714128.
26. Rather PA, Hassan I. Human demodex mite: the versatile mite of dermatological importance. Indian J Dermatol. 2014 Jan;59(1):60-6. doi: 10.4103/0019-5154.123498, PMID 24470662.
27. Dourmishev AL, Dourmishev LA, Schwartz RA. Ivermectin: pharmacology and application in dermatology. Int J Dermatol. 2005 Dec;44(12):981-8. doi: 10.1111/j.1365-4632.2004.02253.x, PMID 16409259.
28. Gowtham S, Karthikeyan K. Wonder drug for worms: a review of three decades of ivermectin use in dermatology. Indian J Dermatol Venereol Leprol. 2019 Nov 1;85(6):674-8. doi: 10.4103/ijdvl.IJDVL_840_18, PMID 31552839.
29. Chhaiya SB, Mehta DS, Kataria BC. Ivermectin: pharmacology and therapeutic applications. Int J Basic Clin Pharmacol. 2012 Nov;1(3):132-9. doi: 10.5455/2319-2003.ijbcp002712.
30. Karthikeyan K, Thappa DM. Cutaneous larva migrans. Indian J Dermatol Venereol Leprol. 2002 Sep 1;68(5):252-8. PMID 17656960.
31. Albrecht H, Franco-Paredes C. Cutaneous larva migrans. Infect Dis. 1998;1998.
32. Shorman M, Al-Tawfiq JA. Strongyloides stercoralis hyperinfection presenting as acute respiratory failure and Gram-negative sepsis in a patient with astrocytoma. Int J Infect Dis. 2009 Sep 1;13(5):e288-91. doi: 10.1016/j.ijid.2008.11.019, PMID 19231269.
33. Boussinesq M. Loiasis: new epidemiologic insights and proposed treatment strategy. J Travel Med. 2012 May 1;19(3):140-3. doi: 10.1111/j.1708-8305.2012.00605.x, PMID 22530819.